Literature DB >> 21627925

Factor VIII safety: plasma-derived versus recombinant products.

Alessandro Gringeri1.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21627925      PMCID： PMC3200403          DOI： 10.2450/2011.0092-10

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  41 in total

Review 1.  The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.

Authors:  E Tabor
Journal:  Transfusion       Date:  1999 Nov-Dec       Impact factor: 3.157

2.  Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients.

Authors:  S G Courter; C L Bedrosian
Journal:  Semin Hematol       Date:  2001-04       Impact factor: 3.851

3.  Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate.

Authors:  C Rouzioux; S Chamaret; L Montagnier; V Carnelli; G Rolland; P M Mannucci
Journal:  Lancet       Date:  1985-02-02       Impact factor: 79.321

4.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

5.  Transmission of non-A, non-B hepatitis by heat-treated factor VIII concentrate.

Authors:  M Colombo; P M Mannucci; V Carnelli; G F Savidge; C Gazengel; K Schimpf
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

6.  Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-01-03       Impact factor: 17.586

7.  Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.

Authors:  Alessandro Gringeri; Lorenzo G Mantovani; Luciana Scalone; Pier Mannuccio Mannucci
Journal:  Blood       Date:  2003-06-19       Impact factor: 22.113

Review 8.  The epidemiology of inhibitors in haemophilia A: a systematic review.

Authors:  J Wight; S Paisley
Journal:  Haemophilia       Date:  2003-07       Impact factor: 4.287

Review 9.  The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Authors:  Günter Auerswald; Torsten Spranger; Hans-Hermann Brackmann
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941

10.  Virus safety of solvent/detergent-treated antihaemophilic factor concentrate.

Authors:  M S Horowitz; C Rooks; B Horowitz; M W Hilgartner
Journal:  Lancet       Date:  1988-07-23       Impact factor: 79.321
View more
  14 in total

1.  Factor VIII inhibitor and source of replacement therapy.

Authors:  Pier Mannuccio Mannucci; Alessandro Gringeri; Elena Santagostino; Flora Peyvandi
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

2.  Clinical and organisational aspects of haemophilia care: the patients' view.

Authors:  Gabriele Calizzani; Romano Arcieri
Journal:  Blood Transfus       Date:  2011-09-21       Impact factor: 3.443

Review 3.  Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Liviana Catalano; Rosa Chianese; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 4.  Present and future challenges in the treatment of haemophilia: the patient's perspective.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 5.  The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Authors:  Gabriele Calizzani; Samantha Profili; Fabio Candura; Monica Lanzoni; Stefania Vaglio; Livia Cannata; Giancarlo M Liumbruno; Massimo Franchini; Pier Mannuccio Mannucci; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

Review 6.  The modern treatment of haemophilia: a narrative review.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 7.  Uncovered needs in the management of inherited bleeding disorders in Italy.

Authors:  Romano Arcieri; Angelo C Molinari; Stefania Farace; Giuseppe Mazza; Alberto Garnero; Gabriele Calizzani; Paola Giordano; Emily Oliovecchio; Lorenzo Mantovani; Lamberto Manzoli; Paul Giangrande
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 8.  Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.

Authors:  Alexandra Sherman; Moanaro Biswas; Roland W Herzog
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

9.  Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).

Authors:  Claudia Djambas Khayat; Genadi Iosava; Irina Romashevskaya; Oleksandra Stasyshyn; Marta Julia Lopez; Maria Teresa Pompa; Tobias Rogosch; Wilfried Seifert
Journal:  J Blood Med       Date:  2021-06-21

Review 10.  Issues in pediatric haemophilia care.

Authors:  Paola Giordano; Massimo Franchini; Giuseppe Lassandro; Maria Felicia Faienza; Roberto Valente; Angelo Claudio Molinari
Journal:  Ital J Pediatr       Date:  2013-04-20       Impact factor: 2.638
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.